Posters

      Cardiovascular Effects Observed When Using the Tobacco Heating System (THS) 2.2 Compared with Continued Smoking

      Baker, G.; Haziza, C.; Hoeng, J.; Ivanov, N.; Luedicke, F.; Maeder, S.; Peitsch, M.; Phillips, B.; Picavet, P.; Poussin, C.; Vanscheeuwijck, P.

      Conference date
      Sep 16, 2018
      Conference name
      73th Congresso Brasileiro de Cardiologica
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      Pre-clinical and clinical studies in COPD and cardiovascular areas and the role of biomarkers

      Systems Toxicology Clinical

      Xenobiotic metabolism response to 3R4F or THS2.2 exposure: from pre-clinical to clinical

      Systems Toxicology Clinical

      Physiological Measures and Novel Sputum Biomarkers to Distinguish Subjects with Mild to Moderate COPD from Asymptomatic Current Smokers, Former Smokers and Never-Smokers

      Systems Toxicology Clinical

      Molecular markers of early stage COPD in serum, sputum, and nasal epithelium from a case-control study

      Systems Toxicology Clinical

      Molecular biomarkers elucidate the role of inflammation and oxidative stress in smoking-related diseases

      Systems Toxicology Clinical

      Cardiovascular Effects Observed When Using the Tobacco Heating System (THS) 2.2 Compared with Continued Smoking

      Systems Toxicology Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.